Department of Defense Prostate Cancer Research Program (CDMRP-PCRP)
The PROMISE Registry - A prostate Cancer genetic research registry.
The Congressionally Directed Department of Defense Prostate Cancer Research Program is one of the most effective federally funded prostate cancer research programs. It has a long history of funding cutting edge prostate cancer research. -The Prostate Cancer Research Program prioritizes research that will 1) distinguish aggressive from indolent disease in men newly diagnosed with prostate cancer, 2) develop strategies to prevent progression to lethal prostate cancer, 3) develop effective treatments and address mechanisms of resistance for men with high risk or metastatic prostate cancer, and 4) develop strategies to optimize the physical and mental health of men with prostate cancer. The focus areas for funded research include bio-marker development, genetics, imaging, mechanisms of resistance, survivorship and palliative care, therapy, and tumor and micro-environment biology.
Cancer ABCs, through its members and the CEO/Executive Director, have a long history of serving both as scientific peer reviewers as well as on the Programmatic Committee which makes all the final funding recommendations and develops the award mechanisms.
————————————————————————————
In the fight against prostate cancer, your DNA may be our most powerful tool.
JOIN US AT:
ProstateCancerPromise.org
Introducing a new collaboration of doctors, researchers, and
patients to bring the power of precision medicine to the fight
against prostate cancer. PROMISE is a registry of prostate cancer
patients participating in a research study to learn how genetic
differences can affect patient outcomes.
PROMISE is Free
No Fees and No Co-pays
PROMISE will not sell your data
Your genetic, medical and personal data
will be used for research only.
PROMISE will work with your current
doctor. You don’t even have to leave
your home.
PROMISE is safe and secure. Your data
Is anonymous and secure.
YOUR GENES MATTER
If we want to understand prostate cancer, we have to understand genes.
That’s why new research on genes of prostate cancer patients is so important.
This research represents the next step in the
collective fight against this disease.
PROMISE is creating a coalition across institutions and building a
registry of prostate cancer patients’ databases so every prostate
cancer patient can understand their genetic risk and potential
treatment options. When we can analyze genetic information
from partners around the country, we will set the foundation for
the future of prostate cancer knowledge and treatment.
JOIN US
ProstateCancerPromise.org
The Metastatic Prostate Cancer Project
COUNT ME IN
Cancer ABCs is one of the founding members of the Prostate Cancer Project (AKA Count Me In). The other founding partners are Harvard University, MIT, The Broad Institute, Prostate Cancer International, and Mr. Jack Whelan.
The project is actively gathering genomic information and treatment outcomes from men living in the United States who have been diagnosed with metastatic prostate cancer.
The project will also feedback any trends identified to all men who participate in the study. It is possible that with a consultation with your medical professional you might be able to better understand your own cancer.
For more information about the project send a request to: info@PCproject.org. To begin the registration process go to: www.PCproject.org
PROTECT and TRANSLATE Clinical Trials
PUBLICATION:
Darolutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer: A Patient Perspective of the ARAMIS Trial
Cancer ABCs has been actively working with the sponsors of clinical trials to ensure that the patient voice is a part of all trial development. Cancer ABCs works to make sure that as clinical trials are developed so that the patient perspective and the patient’s concerns are always considered first and foremost in the design of the trial. Cancer ABCs has actively worked with numerous organizations to ensure that the patient voice is a part of clinical trials. Organizations have included: Prostate Clinical Trial Consortium (PCCTC), The Broad Institute, Pfizer Oncology, Janssen Pharmaceutical (Johnson & Johnson),
Darolutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer: A Patient Perspective of the ARAMIS Trial
K Fizazi1 (ARAMIS trial investigator and oncologist), Ian Blue2 (ARAMIS trial participant) & Joel T Nowak2,3 (prostate cancer thriver and patient advocate) -1Institut Gustave Roussy, Villejuif, France; 2 Patient author; 3Cancer ABCs, Brooklyn, NY, USA
Plain Language Summary of Publication Published in Future Oncology, online: 8 February 2021
This is a summary of a publication about the ARAMIS (Androgen Receptor Antagonizing Agent for Metastasis-free Survival) trial, which was published in the New England Journal of Medicine in September 2020. The trial was in adult participants with nonmetastatic, castrationresistant prostate cancer (nmCRPC) who received a trial treatment called darolutamide (brand name Nubeqa®).
The ARAMIS trial looked at darolutamide taken by mouth in 1509 participants from 36 countries with nmCRPC (prostate cancer that has not spread to other parts of the body and no longer responds adequately to initial hormone therapy).
The trial showed that darolutamide in addition to hormone therapy increased the length of time that the trial participants were still alive for and lowered the risk of death by 31% compared with placebo (sugar pill) and hormone therapy.
The participants who received darolutamide and hormone therapy also had longer time to worsening pain, needing chemotherapy, and having cancer-related bone fractures or symptoms related to cancer-related bone fracture compared with those who received placebo and hormone therapy during the trial.
In general, the percentage of participants who experienced medical problems (referred to as adverse events) was similar between those who received darolutamide and those who received placebo, in addition to hormone therapy.
This summary also includes insights and perspectives from a participant who was in the ARAMIS trial and from a prostate cancer patient advocate
A PHASE II CLINICAL TRIAL EVALUATING ATEZOLIZUMAB, ABIrATERONE AND SBRT IN MEN WITH M1B CASTRATE SENSITIVE PROSTATE CANCER
THE DORA TRAIL
EVALUATING RADIUM-223 (XOFIGO) IN COMBINATION WITH THE CHEMOTHERAPY DRUG DOCETAXEL
IRONMAN – AN INTERNATIONAL REGISTRY FOR MEN WITH ADVANCED PROSTATE CANCER ACCELERATING OUR KNOWLEDGE AND UNDERSTANDING ABOUT ADVANCED PROSTATE CANCER, ITS TREATMENTS AND ITS OUTCOMES
We have received funding from Stand-Up To Cancer to launch this trial. This is a single arm study that will evaluate atezolizumab with ADT, abiraterone and SBRT in 42 men with newly diagnosed hormone sensitive prostate cancer. It will evaluate the potential of combining SBRT with an anti-PD-L1 immunotherapy. Cancer ABCs is working with researchers at Memorial Sloane Kettering Cancer Center and Columbia University Medical Center. The coordinating agency is the Prostate Cancer Clinical Trial Consortium.
THE DORA TRIAL
This is a clinical trial that is designed to test Radium-223 (Xofigo) in combination with the chemotherapy drug Docetaxel in men with prostate cancer.
This trial is actively recruiting. More information is available at: https://clinicaltrials.gov/ct2/show/NCT03574571
The overall goal of the study phase III open label randomized clinical trial is to compare the good and bad effects of using radium-223 (Xofigo) along (in combination) with docetaxel chemotherapy treatment verses using docetaxel alone.
The study has 46 active sites worldwide. The Principal Investigator is Michael Morris, MD from Memorial Sloane Kettering Cancer Center in New York City. The Prostate Cancer Clinical Trial Consortium (PCCTC) is the sponsor of this study and Cancer ABCs are the patient advocates.
Contact: Michael Morris, MD 646-422-4469 morrism@mskcc.org
Contact: Josef Fox, MD 212-639-7371
ClinicalTrials.gov Identifier: NCT03574571
IRONMAN is an international registry of men with advanced prostate cancer. From 2017-2022, we’ll sign-up at least 5,000 men from 14 countries with advanced prostate cancer to join the registry. The registry is working to better understand more about advanced prostate cancer treatment, side effects, the care, and out comes provide to men with advanced prostate cancer.
The Registry collects
· Patient’s medical history
· Treatment information
· Blood samples.
· Health surveys that let us measure their quality of life.
IRONMAN believes that by collecting this information and blood samples, we will quickly understand which treatment and care practices deliver the best outcomes for men with advanced prostate cancer. We will then share this knowledge across the globe, so that all men can benefit
IRONMAN has also established a prospective blood biorepostory for all men in the registry. Blood specimens will be collected at baseline enrolment, and then again at the first treatment change or at one-year follow-up. Specimens will be collected, processed, and stored as plasma, cell free DNA, buffy coat / RNA for future biomarker studies. Samples will be stored in country-specific biorepositories.
For More Information and to Enroll Go To:
IRONMAN is a project of the Prostate Cancer Clinical Trial Consortium (PCCTC) and
Cancer ABCs serve as the patient advocates for the registry
IRONMAN IS FUNDED BY MOVEMBER
